A Patient with Corneal Epithelial Disorder That Developed after Administration of a Latanoprost Generic, but Not a Brand-Name Drug, Eye Drop
Background. We report a patient who developed corneal epithelial disorder repeatedly after changing the prescription from Xalatan eye drops (Pfizer Inc.) to Latanoprost eye drops (Kaken Pharmaceutical Co., Ltd.), both containing 0.005% latanoprost. Case Report. An 88-year-old male with glaucoma had...
Main Authors: | Yukihisa Takada, Yuka Okada, Norihito Fujita, Shizuya Saika |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Case Reports in Ophthalmological Medicine |
Online Access: | http://dx.doi.org/10.1155/2012/536746 |
Similar Items
-
A Case of Solitary Nonvascularized Corneal Epithelial Dysplasia
by: Tomoya Morii, et al.
Published: (2016-01-01) -
Severe cutaneous reaction to latanoprost eye drops
by: Ivan Yeu Ming Yip, et al.
Published: (2018-01-01) -
Latanoprost eye drops induce conjunctival lymphatic vessel development
by: Kai Ma, et al.
Published: (2021-09-01) -
Histopathological Features in a Case of Peters' Anomaly with Acquired Corneal Staphyloma
by: Kumi Shirai, et al.
Published: (2011-01-01) -
Treatment of Recurrent Corneal Epithelial Defect by Autologous Serum Eye Drop
by: Hossein Mohammad Rabei, et al.
Published: (2015-02-01)